Protocol Ledger

NCT05651711 · Phase III · COMPLETED

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Interventional Phase III clinical trial protocol NCT05651711 sponsored by Amgen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-14 Enrollment: 726 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05651711
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)726 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05651711
Protocol FieldVerified Registry Value
NCT IdentifierNCT05651711
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment726 participants (ACTUAL)
Registered Start Date2022-12-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05651711
Hospital Research SiteLocationSite Profile
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->
Velocity Clinical Research (La Mesa)La Mesa, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI